12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Interprotein, RaQualia deal

The companies partnered to discover and develop protein-protein interaction inhibitors for undisclosed pain indications. RaQualia will be responsible for discovering candidates, while Interprotein will use its Engine for New Drug Design (INTENDD) technology...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >